-
Technology Transactions Veteran
Ian has nearly 30 years of business and legal experience representing life sciences clients in strategic alliances, agreements, arrangements, collaborations, and joint ventures.
-
Prominent Life Sciences and Medtech Clients
Ian has represented numerous well-known life sciences and medtech companies, including Illumina, Mylan, Pfenex, and Zymeworks.
-
A Recognized Practitioner
Ian has been recognized as a leader in his field by Chambers USA.
Ian Edvalson is a technology transactions partner in Wilson Sonsini Goodrich & Rosati’s Palo Alto office and a former member of the firm’s board of directors. Ian advises numerous domestic and international public and private biopharmaceutical, medtech, and life sciences companies with all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to the structuring and negotiating of a wide range of arrangements designed to maximize the value of their businesses.
Ian specializes in working with his clients on the most complex strategic alliances and joint ventures for the development and marketing of all stages of pharmaceutical and other products. In addition, he helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements.
Ian draws on his almost 30 years of business and legal experience (including his time leading the corporate and business development functions at Third Wave Technologies, a public genomics company) to address the full range of issues and transactions facing biopharmaceutical, medtech, and life sciences companies. He works closely with his clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.
Ian Edvalson is a technology transactions partner in Wilson Sonsini Goodrich & Rosati’s Palo Alto office and a former member of the firm’s board of directors. Ian advises numerous domestic and international public and private biopharmaceutical, medtech, and life sciences companies with all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to the structuring and negotiating of a wide range of arrangements designed to maximize the value of their businesses.
Ian specializes in working with his clients on the most complex strategic alliances and joint ventures for the development and marketing of all stages of pharmaceutical and other products. In addition, he helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements.
Ian draws on his almost 30 years of business and legal experience (including his time leading the corporate and business development functions at Third Wave Technologies, a public genomics company) to address the full range of issues and transactions facing biopharmaceutical, medtech, and life sciences companies. He works closely with his clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.
- J.D., University of Chicago Law School
- B.S., Molecular Biology, Brigham Young University
- B.A., Korean, Brigham Young University
- Named in the 2007-2017 and 2021-2023 editions of Chambers USA: America's Leading Lawyers for Business
- Named in Northern California Super Lawyers in 2011, 2013, 2014, and 2015
- State Bar of California
- J.D., University of Chicago Law School
- B.S., Molecular Biology, Brigham Young University
- B.A., Korean, Brigham Young University
- Named in the 2007-2017 and 2021-2023 editions of Chambers USA: America's Leading Lawyers for Business
- Named in Northern California Super Lawyers in 2011, 2013, 2014, and 2015
- State Bar of California
Illustrative Representations
- ABL Bio in its exclusive collaboration and worldwide license agreement with SANOFI
- Armagen in its collaboration with Shire for treatments of Hunter Syndrome
- Astellas in its joint venture with CVC Investments
- Biomarin in its joint venture with Sanofi (Genzyme)
- Caribou Biosciences in its co-founding and licensing of Intellia Therapeutics for therapeutic products based on CRISPR-Cas technologies and cross-license with DuPont for foundational CRISPR-Cas technologies and products
- Cytopia in its research and license arrangement with Novartis for JAK3 products
- Durect in its license with Gilead for long-acting HIV, HBV, and HVC products, asset transfer arrangement with Impax Laboratories for Eladur, and in its alliance with Santen for a sustained-release SABER ophthalmology product
- Gilead Sciences in its acquisition of YM Biosciences and in its license from Theraclone for its broadly neutralizing HIV antibodies
- Illumina in its license and supply arrangement with Natera for certain diagnostic products and technologies
- Mesoblast in various strategic alliances including with Grunenthal, Lonza, JCR, and Tasly for its cell therapy products
- Mylan in various strategic alliances including with Biocon for various biosimilar products and with Pfizer for the commercialization of EpiPen, multiple generic products for Japan, and development and commercialization of proprietary inhalable products
- Pacific Biosystems in its acquisition by Illumina and its collaboration with F. Hoffman-La Roche for specific diagnostic products and platforms
- Parvus Therapeutics in its collaborations with Roche/Genentech and Novartis for its tolerogenic nanoparticle products
- Pfenex in its worldwide marketing arrangement with Alvogen, its joint venture with Agila Biotech for various biosimilar products and in its license and option transaction with Jazz Pharmaceuticals for hematological malignancy products
- Schiff Nutrition in its acquisition of Ganrden Biotech
- Shin Nippon Biomedical Laboratories in its license with Transcept for a nasally-delivered DHE product
- Taiho Pharmaceuticals in its licenses with PharmaMar for Yondelis and with Teva for Actiq
- Tolero Pharmaceuticals in its acquisition by Sumitomo Dainippon Pharmaceuticals and licenses with Sanofi and Mannkind
- Verily Life Sciences in its collaborations with Dexcom and Proctor & Gamble
- Y’s Therapeutics in its acquisition of certain assets from Thios Pharmaceuticals
- Zymeworks in its strategic alliances with Celgene, Eli Lilly, Glaxo SmithKline, and Merck to design, develop, and commercialize proprietary bi-specific antibodies
Illustrative Representations
- ABL Bio in its exclusive collaboration and worldwide license agreement with SANOFI
- Armagen in its collaboration with Shire for treatments of Hunter Syndrome
- Astellas in its joint venture with CVC Investments
- Biomarin in its joint venture with Sanofi (Genzyme)
- Caribou Biosciences in its co-founding and licensing of Intellia Therapeutics for therapeutic products based on CRISPR-Cas technologies and cross-license with DuPont for foundational CRISPR-Cas technologies and products
- Cytopia in its research and license arrangement with Novartis for JAK3 products
- Durect in its license with Gilead for long-acting HIV, HBV, and HVC products, asset transfer arrangement with Impax Laboratories for Eladur, and in its alliance with Santen for a sustained-release SABER ophthalmology product
- Gilead Sciences in its acquisition of YM Biosciences and in its license from Theraclone for its broadly neutralizing HIV antibodies
- Illumina in its license and supply arrangement with Natera for certain diagnostic products and technologies
- Mesoblast in various strategic alliances including with Grunenthal, Lonza, JCR, and Tasly for its cell therapy products
- Mylan in various strategic alliances including with Biocon for various biosimilar products and with Pfizer for the commercialization of EpiPen, multiple generic products for Japan, and development and commercialization of proprietary inhalable products
- Pacific Biosystems in its acquisition by Illumina and its collaboration with F. Hoffman-La Roche for specific diagnostic products and platforms
- Parvus Therapeutics in its collaborations with Roche/Genentech and Novartis for its tolerogenic nanoparticle products
- Pfenex in its worldwide marketing arrangement with Alvogen, its joint venture with Agila Biotech for various biosimilar products and in its license and option transaction with Jazz Pharmaceuticals for hematological malignancy products
- Schiff Nutrition in its acquisition of Ganrden Biotech
- Shin Nippon Biomedical Laboratories in its license with Transcept for a nasally-delivered DHE product
- Taiho Pharmaceuticals in its licenses with PharmaMar for Yondelis and with Teva for Actiq
- Tolero Pharmaceuticals in its acquisition by Sumitomo Dainippon Pharmaceuticals and licenses with Sanofi and Mannkind
- Verily Life Sciences in its collaborations with Dexcom and Proctor & Gamble
- Y’s Therapeutics in its acquisition of certain assets from Thios Pharmaceuticals
- Zymeworks in its strategic alliances with Celgene, Eli Lilly, Glaxo SmithKline, and Merck to design, develop, and commercialize proprietary bi-specific antibodies
Select Speaking Engagements
- “Building Successful Corporate Partnerships,” HealthTech Conference
- “The Challenges of Pharma and Biotech in Emerging Markets—Focus on China and India,” AusBiotech
- “Where does Biopharma go from here?” EPPIC Annual Conference
- “Licensing Strategies—Views from the Trenches,” The Bio2Device Group
Select Speaking Engagements
- “Building Successful Corporate Partnerships,” HealthTech Conference
- “The Challenges of Pharma and Biotech in Emerging Markets—Focus on China and India,” AusBiotech
- “Where does Biopharma go from here?” EPPIC Annual Conference
- “Licensing Strategies—Views from the Trenches,” The Bio2Device Group
- Privacy Policy
- Terms of Use
- Accessibility